Anti-COVID property of subcutaneous ivermectin in synergy with zinc among midlife moderately symptomatic patients: a structured summary of a study protocol for a randomised controlled trial.
Ashraf S, Ashraf S, Farooq I, Ashraf S, Ashraf M, Imran MA, Kalsoom L, Akmal R, Ghufran M, Rafique S, Akram MK, Habib Z, Siddiqui UN, Ahmad A, Arshad S, Virk MAR, Gul M, Awais AB, Hassan M, Sherazi SSH, Safdar Z, Munir I, Khalid H, Munir K, Majeed N, Alahmadi YM, Humayun A, Saboor QA, Ahmad A, Ashraf M, Izhar M; DOCTORS LOUNGE Consortium.
. Schoenfeld AJ, et al. Ann Oncol. 2021 Sep 3:S0923-7534(21)04455-0. doi: 10.1016/j.annonc.2021.08.2151. Online ahead of print. Ann Oncol. 2021. PMID: 34487855
. Marconi VC, et al. Lancet Respir Med. 2021 Aug 31:S2213-2600(21)00331-3. doi: 10.1016/S2213-2600(21)00331-3. Online ahead of print. Lancet Respir Med. 2021. PMID: 34480861
. Nawa N, et al. J Epidemiol. 2021 Aug 12. doi: 10.2188/jea.JE20210197. Online ahead of print. J Epidemiol. 2021. PMID: 34380919
. No abstract available.
![top](data:image/svg+xml,%3Csvg%20xmlns="http://www.w3.org/2000/svg"%20width="16"%20height="16"%3E%3Crect%20fill-opacity="0"/%3E%3C/svg%3E "top")
